Social Media Ideas for Aacr D3 2026

AACR D3: The ‘Global One-stop Conference’ for Drug Discovery and Development

The inaugural AACR Drug Discovery and Development (AACR D3) meeting will convene experts to reshape the future of oncology therapeutics. The post AACR D3: The ‘Global One-stop Conf...

At the AACR Annual Meeting 2026, Cancer Grand Challenges Teams Explore How Cancer Forms and Evolves

At the AACR Annual Meeting 2026, a session highlighted progress from four Cancer Grand Challenges teams on the interplay of mutations, promoting factors, and tissue-specific epigen...

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-...

Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third...

AACR Annual Meeting 2026: Bite-sized Research

At the AACR Annual Meeting 2026, we conducted "Bite-sized Research" interviews with attendees for morsels of knowledge about their work, including Brian G. Morreale, PhD, of the Un...

AACR Annual Meeting 2026 Presidential Sessions Explore Cancer Interception and Prevention

At the AACR Annual Meeting 2026, Lillian Siu shared her research into cancer interception and assembled a panel to discuss targeted cancer prevention. The post AACR Annual Meeting...

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer admin Thu, 05/28/2026 - 11:51 Steady progress across the board today, with new appro...

FDA Approvals in Oncology: April-June 2026 

During the second quarter of 2026, oncology approvals issued by the U.S. Food and Drug Administration expanded the treatment options available for patients with breast cancer, urin...

Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastat...

Highlights of ASCO 2026: how is cancer care evolving? 

Labiotech heard from experts about the major trends and highlights in cancer care at ASCO 2026. The post Highlights of ASCO 2026: how is cancer care evolving?  appeared first on L...

ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.

PDSB Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. DATEWednesday, May 13, 2026 at 8 a.m. ETCALL PARTICIPANTSChief Executive Officer — Frank Bedu-AddoChief Medical Officer — Kirk ShepardChief Financia...

From the Bench, AACR Annual Meeting 2026: Innovative Tools Uncover New Insights Into Cancer 

The latest edition of our "From the Bench" series examines creative research approaches presented at the AACR Annual Meeting 2026 enabling new insights into cancer. The post From t...

ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential

CHICAGO, May 31, 2026 /PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, Ori-C101, a GPC3-...

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedi...

AWM 2026 Direction

AWM 2026 Direction Anonymous (not verified) Mon, 06/15/2026 - 20:55 field_thread_url https://cafepharma.com/boards/threads/awm-2026-direction.712673/...

Editors’ Picks, June 2026: Preventing Colorectal Cancer, Targeting Neural Cross-talk to Stop Glioblastoma Recurrence, an...

The June edition of Editors’ Picks from the AACR journals included studies on targeting neural cross-talk to stop glioblastoma recurrence, identifying patients with multiple myelom...

Data Amplified 2026: Simpler, Smarter, Structured -- From Data to Insight

Data Amplified 2026 will be held on 26-27 October 2026 in The Hague, the Netherlands, with the theme "Simpler, smarter, structured: from data to insight." It will reveal the next g...

Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer P...

SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...

Medical Research Charity Showcase 2026

The 2026 showcase built on the inaugural event, featuring a wider range of interactive exhibits demonstrating the impact of charity-funded medical research. See our news story on...

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple...

First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups

Revolution Medicines, Daraxonrasib, and the New Race to Drug KRAS Cancer

Revolution Medicines, Daraxonrasib, and the New Race to Drug KRAS Cancer For decades, one of the most important cancer targets was also one of the most frustrating. Scientists knew...

Daré (DARE) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. DATEThursday, March 26, 2026 at 4:30 p.m. ETCALL PARTICIPANTSPresident & Chief Executive Officer — Sabrina Martucci JohnsonChief Accounting Offi...

UK3CR joins CCTG and EORTC in welcoming G7 commitment to accelerate global progress against cancer

Published: 24 June 2026 The Canadian Cancer Trials Group (CCTG), the European Organisation for Research and Treatment of Cancer (EORTC), and the UK Collaborative for Cancer Clinic...

ASCO: Celcuity dares to dream of becoming $10B company after breast cancer win over Piqray

While Revolution Medicines dominated this year’s American Society of Clinical Oncology annual meeting by conquering the “undruggable” RAS pathway, another up-and-coming biotech hop...